BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34137937)

  • 1. Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype.
    Mazzini FN; Cook F; Gounarides J; Marciano S; Haddad L; Tamaroff AJ; Casciato P; Narvaez A; Mascardi MF; Anders M; Orozco F; Quiróz N; Risk M; Gutt S; Gadano A; Méndez García C; Marro ML; Penas-Steinhardt A; Trinks J
    Metabolomics; 2021 Jun; 17(7):58. PubMed ID: 34137937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.
    Liao S; An K; Liu Z; He H; An Z; Su Q; Li S
    J Clin Lab Anal; 2022 Sep; 36(9):e24626. PubMed ID: 35881683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    Liu WY; Zheng KI; Pan XY; Ma HL; Zhu PW; Wu XX; Rios RS; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1057-1064. PubMed ID: 31677195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of metabolic syndrome and patatin-like phospholipase 3 - rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population.
    Narayanasamy K; Karthick R; Panneerselvam P; Mohan N; Ramachandran A; Prakash R; Rajaram M
    J Gene Med; 2020 Apr; 22(4):e3160. PubMed ID: 31945251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants.
    Del Ben M; Polimeni L; Brancorsini M; Di Costanzo A; D'Erasmo L; Baratta F; Loffredo L; Pastori D; Pignatelli P; Violi F; Arca M; Angelico F
    Eur J Intern Med; 2014 Jul; 25(6):566-70. PubMed ID: 24947770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population.
    Lee Y; Cho EJ; Choe EK; Kwak MS; Yang JI; Oh SW; Yim JY; Chung GE
    Sci Rep; 2024 Apr; 14(1):9753. PubMed ID: 38679617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.
    Walker RW; Belbin GM; Sorokin EP; Van Vleck T; Wojcik GL; Moscati A; Gignoux CR; Cho J; Abul-Husn NS; Nadkarni G; Kenny EE; Loos RJF
    J Hepatol; 2020 Jun; 72(6):1070-1081. PubMed ID: 32145261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels.
    Sun DQ; Zheng KI; Xu G; Ma HL; Zhang HY; Pan XY; Zhu PW; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Zheng MH
    Liver Int; 2020 Jan; 40(1):107-119. PubMed ID: 31519069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
    Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
    J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease.
    Hotta K; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Chayama K; Nakajima A; Nakao K; Sekine A
    BMC Med Genet; 2010 Dec; 11():172. PubMed ID: 21176169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
    Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of single nucleotide polymorphism at PNPLA3 with fatty liver, steatohepatitis, and cirrhosis of liver.
    Alam S; Islam MS; Islam S; Mustafa G; Saleh AA; Ahmad N
    Indian J Gastroenterol; 2017 Sep; 36(5):366-372. PubMed ID: 28975533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes.
    Xia MF; Lin HD; Chen LY; Wu L; Ma H; Li Q; Aleteng Q; Hu Y; He WY; Gao J; Bian H; Li XY; Gao X
    Diabetologia; 2019 Apr; 62(4):644-654. PubMed ID: 30673802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders.
    Xia MF; Ling Y; Bian H; Lin HD; Yan HM; Chang XX; Li XM; Ma H; Wang D; Zhang LS; Wang SS; Wu BJ; He WY; Zhao NQ; Gao X
    Aliment Pharmacol Ther; 2016 Mar; 43(5):631-42. PubMed ID: 26765961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated analysis of the transcriptome and its interaction with the metabolome in metabolic associated fatty liver disease: Gut microbiome signatures, correlation networks, and effect of PNPLA3 genotype.
    Mascardi MF; Mazzini FN; Suárez B; Ruda VM; Marciano S; Casciato P; Narvaez A; Haddad L; Anders M; Orozco F; Tamaroff AJ; Cook F; Gounarides J; Gutt S; Gadano A; García CM; Marro ML; Penas Steinhardt A; Trinks J
    Proteomics; 2023 Sep; 23(18):e2200414. PubMed ID: 37525333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients.
    Tai CM; Huang CK; Tu HP; Hwang JC; Yeh ML; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
    Medicine (Baltimore); 2016 Mar; 95(12):e3120. PubMed ID: 27015186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis.
    Finkenstedt A; Auer C; Glodny B; Posch U; Steitzer H; Lanzer G; Pratschke J; Biebl M; Steurer M; Graziadei I; Vogel W; Zoller H
    Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1667-72. PubMed ID: 23872669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis.
    Tang S; Zhang J; Mei TT; Guo HQ; Wei XH; Zhang WY; Liu YL; Liang S; Fan ZP; Ma LX; Lin W; Liu YR; Qiu LX; Yu HB
    BMC Med Genet; 2020 Aug; 21(1):163. PubMed ID: 32811452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.